Trial
NCT04405167
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Pennsylvania
Collaborators
Active Biotech AB
Condition
Multiple Myeloma
Intervention
Tasquinimod
Why stopped
Slow accrual at the time when sufficient participants were already enrolled to answer the scientific question posed by the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-07